Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 18/20 | 0.72 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13863924 | 0.85 | MEN1 (0.73) | TRPV1MEN1KMT2A | |
| SCHEMBL5934589 | 0.84 | TRPV1 (1.00) | TRPV1 | |
| SCHEMBL14084057 | 0.83 | TRPV1 (0.73) | TRPV1 | |
| SCHEMBL4428855 | 0.83 | MEN1 (0.67) | TRPV1MEN1KMT2A | |
| SCHEMBL14084047 | 0.83 | TRPV1 (0.90) | TRPV1 | |
| SCHEMBL14084075 | 0.82 | TRPV1 (0.79) | TRPV1 | |
| SCHEMBL6363975 | 0.82 | TRPV1 (0.82) | TRPV1 | |
| SCHEMBL15779637 | 0.82 | TRPV1 (1.00) | TRPV1 | |
| SCHEMBL14084072 | 0.81 | TRPV1 (0.70) | TRPV1 | |
| SCHEMBL6369466 | 0.81 | TRPV1 (0.77) | TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050165049-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN, INC. | 2005-07-28 | — | — | US | claimed |
| US-7544803-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2009-06-09 | — | — | US | disclosed |
| US-7544803-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2009-06-09 | — | — | US | disclosed |
| US-7544803-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2009-06-09 | — | — | US | disclosed |
| US-20050165049-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN, INC. | 2005-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165049-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | TRPV1 1/4885MEN1 3499/4885KMT2A 3902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.